CR10024A - Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos - Google Patents
Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismosInfo
- Publication number
- CR10024A CR10024A CR10024A CR10024A CR10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A
- Authority
- CR
- Costa Rica
- Prior art keywords
- egfr
- vegf
- methods
- links
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se dan a conocer ligandos que tienen especificidad de enlace para el factor de crecimiento endotelial vascular (VEGF), para el receptor del factor de crecimiento epidérmico (EGFR), o para VEGF y EGFR. También se dan a conocer métodos para utiliazar estos ligandos. En particular, se describe el uso de estos ligandos para la terapia de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74299205P | 2005-12-06 | 2005-12-06 | |
US75835506P | 2006-01-11 | 2006-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10024A true CR10024A (es) | 2008-09-22 |
Family
ID=37820653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10024A CR10024A (es) | 2005-12-06 | 2008-05-27 | Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos |
Country Status (13)
Country | Link |
---|---|
US (2) | US20100056439A1 (es) |
EP (1) | EP1966242A1 (es) |
JP (1) | JP2009518024A (es) |
KR (1) | KR20080077261A (es) |
AU (1) | AU2006323412A1 (es) |
BR (1) | BRPI0619463A2 (es) |
CA (1) | CA2632417A1 (es) |
CR (1) | CR10024A (es) |
EA (1) | EA013878B1 (es) |
MA (1) | MA30021B1 (es) |
NO (1) | NO20082386L (es) |
TW (1) | TW200804425A (es) |
WO (1) | WO2007066106A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
EA023031B1 (ru) * | 2007-11-30 | 2016-04-29 | Глаксо Груп Лимитед | Антиген-связывающая конструкция и ее применение |
CA2707986A1 (en) * | 2007-12-13 | 2009-06-18 | Glaxo Group Limited | Compositions for pulmonary delivery |
US8454960B2 (en) * | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
CA2711256C (en) | 2008-01-03 | 2019-01-15 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
CA2718480A1 (en) | 2008-03-31 | 2009-10-08 | Glaxo Group Limited | Drug fusions and conjugates |
WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
JP2012506237A (ja) * | 2008-10-21 | 2012-03-15 | ドマンティス リミテッド | Dc−signに対する結合特異性をもつリガンド |
BRPI0921319A2 (pt) * | 2008-11-26 | 2018-10-16 | Glaxo Group Ltd | composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica |
BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
CN102405236A (zh) * | 2009-02-19 | 2012-04-04 | 葛兰素集团有限公司 | 改进的抗-tnfr1多肽,抗体可变结构域和拮抗剂 |
JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
WO2010136483A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
EP2454285A2 (en) * | 2009-07-16 | 2012-05-23 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
JP2013518853A (ja) | 2010-02-05 | 2013-05-23 | アブリンクス エン.ヴェー. | 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド |
US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
WO2012022703A2 (en) * | 2010-08-20 | 2012-02-23 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
EP2643351A1 (en) * | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US20140255471A1 (en) | 2013-03-11 | 2014-09-11 | Wake Forest University Health Sciences | Method of treating brain tumors |
EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
ES2779123T3 (es) * | 2013-09-26 | 2020-08-13 | Ablynx Nv | Nanobodies biespecíficos |
WO2016118733A1 (en) | 2015-01-21 | 2016-07-28 | Inhibrx Biopharma LLC | Non-immunogenic single domain antibodies |
AU2016215087A1 (en) | 2015-02-06 | 2017-08-17 | University Of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection |
CN107922491B (zh) | 2015-07-16 | 2021-09-28 | 印希比股份有限公司 | 多价和多特异性结合dr5的融合蛋白 |
KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
EP3768722A4 (en) * | 2018-03-19 | 2021-12-29 | Wuxi Biologics Ireland Limited. | Novel anti-egfr antibody polypeptide |
CA3134680C (en) * | 2019-03-29 | 2024-02-06 | Green Cross Corporation | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof |
WO2022047169A1 (en) * | 2020-08-28 | 2022-03-03 | Trustees Of Boston University | Engineered extracellular receptor constructs and uses thereof |
CN115724968B (zh) * | 2021-08-27 | 2023-08-08 | 三优生物医药(上海)有限公司 | Vegf结合分子及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2170257C2 (ru) * | 1994-03-17 | 2001-07-10 | Мерк Патент Гмбх | Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли |
AU733674B2 (en) * | 1996-10-25 | 2001-05-24 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
CA2286330C (en) * | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
AU2002211658A1 (en) * | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
RU2430927C2 (ru) * | 2000-10-20 | 2011-10-10 | Тугаи Сейяку Кабусики Кайся | Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу |
US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
EP2267032A3 (en) * | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
EP1639011B1 (en) * | 2003-06-30 | 2008-11-12 | Domantis Limited | Pegylated single domain antibodies (dAb) |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
ATE485307T1 (de) * | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
US20090252681A1 (en) * | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
-
2006
- 2006-12-05 AU AU2006323412A patent/AU2006323412A1/en not_active Abandoned
- 2006-12-05 BR BRPI0619463-0A patent/BRPI0619463A2/pt not_active IP Right Cessation
- 2006-12-05 EP EP06820440A patent/EP1966242A1/en not_active Withdrawn
- 2006-12-05 WO PCT/GB2006/004559 patent/WO2007066106A1/en active Application Filing
- 2006-12-05 CA CA002632417A patent/CA2632417A1/en not_active Abandoned
- 2006-12-05 TW TW095145121A patent/TW200804425A/zh unknown
- 2006-12-05 US US12/086,020 patent/US20100056439A1/en not_active Abandoned
- 2006-12-05 KR KR1020087016537A patent/KR20080077261A/ko not_active Application Discontinuation
- 2006-12-05 JP JP2008543892A patent/JP2009518024A/ja active Pending
- 2006-12-05 EA EA200801172A patent/EA013878B1/ru not_active IP Right Cessation
-
2008
- 2008-05-26 NO NO20082386A patent/NO20082386L/no unknown
- 2008-05-27 CR CR10024A patent/CR10024A/es not_active Application Discontinuation
- 2008-06-02 MA MA30990A patent/MA30021B1/fr unknown
-
2012
- 2012-10-26 US US13/644,414 patent/US20130041136A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA200801172A1 (ru) | 2008-12-30 |
US20100056439A1 (en) | 2010-03-04 |
KR20080077261A (ko) | 2008-08-21 |
EA013878B1 (ru) | 2010-08-30 |
TW200804425A (en) | 2008-01-16 |
JP2009518024A (ja) | 2009-05-07 |
AU2006323412A1 (en) | 2007-06-14 |
BRPI0619463A2 (pt) | 2013-01-08 |
EP1966242A1 (en) | 2008-09-10 |
WO2007066106A1 (en) | 2007-06-14 |
NO20082386L (no) | 2008-08-27 |
MA30021B1 (fr) | 2008-12-01 |
CA2632417A1 (en) | 2007-06-14 |
US20130041136A1 (en) | 2013-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10024A (es) | Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos | |
CR10147A (es) | "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos" | |
CR9819A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
LTPA2017011I1 (lt) | Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui | |
GT200600407A (es) | Compuestos ppar activos | |
DE602005021694D1 (de) | Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung | |
CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
HN2005029978A (es) | Formulaciones | |
CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
ECSP088508A (es) | Antagonistas de neuropilina | |
ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
CO6290772A2 (es) | Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
BRPI0511396A (pt) | derivados de retinal e métodos para uso no tratamento de enfermidades visuais | |
WO2009009173A3 (en) | Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases | |
DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
AR066395A1 (es) | Reovirus que tienen secuencias modificadas | |
CY1111579T1 (el) | Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου | |
DK1951759T3 (da) | Anti-EGFR-antistoffer | |
CY1111629T1 (el) | Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων | |
AR064458A1 (es) | Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos | |
DOP2006000277A (es) | Anticuerpos anti mn y métodos para su utilización | |
CL2008002782A1 (es) | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |